Comparison of iodine-123-iomazenil spect and technetium-99m-HMPAO-SPECT in Alzheimer's disease

Kazuki Fukuchi, Kazuo Hashikawa, Yujiro Seike, Hiroshi Moriwaki, Naohiko Oku, Mariko Ishida, Masahiro Fujita, Toshiisa Uehara, Hirotaka Tanabe, Hideo Kusuoka, Tsunehiko Nishimura

Research output: Contribution to journalArticlepeer-review

Abstract

This study was designed to elucidate a central type of benzodiazepine (Bz) receptor distribution in patients with Alzheimer's disease using SPECT with [123I]iornazenil (IMZ). Methods: Eight patients with probable Alzheimer's disease were studied. Benzodiazepine receptor imaging was performed 15 min (early) and 180 min (delayed) after intravenous administration of 167 MBq IMZ, sequentially, using hexamethylpropylene amine oxime (HMPAO) SPECT to evaluate regional cerebral perfusion. Results: Early IMZ-SPECT depicted areas of reduced uptake in sites of decreased cerebral blood flow (CBF), but each area of decreased uptake was extended wider than the area of hypoperfusion. Delayed IMZ-SPECT images demonstrated a similar pattern of decreased area of CBF; the affected region in Bz receptor bindings, however, was clearer and broader compared with that in either HMPAO-SPECT or early IMZ-SPECT. In comparison with the uptakes for the normal cerebral hemisphere (ratio to the contralateral cerebellum) in patients with unilateral cerebral infarction as a control group (n = 4), the patients with Alzheimer's disease showed distinctive bilateral frontal or parietal defects (p < 0.05). Conclusion: Brain SPECT using IMZ may be more sensitive than CBF images in patients with Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)467-470
Number of pages4
JournalJournal of Nuclear Medicine
Volume38
Issue number3
StatePublished - Mar 1 1997

Keywords

  • Alzheimer's disease
  • Benzodiazepine receptor
  • Iodine-123- iomazenil
  • Technetium-99m-HMPAO

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Comparison of iodine-123-iomazenil spect and technetium-99m-HMPAO-SPECT in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this